Journal article
XALOC-1 Clinical Remission Over 2 Years With Benralizumab in Severe Eosinophilic Asthma
Abstract
BACKGROUND: Long-term real-world data on clinical remission in patients with severe eosinophilic asthma (SEA) receiving biologics are lacking. We describe clinical remission over 2 years in patients with SEA receiving benralizumab.
RESEARCH QUESTION: Is long-term clinical remission a viable goal for patients with SEA receiving benralizumab?
Authors
Pelaia G; Jackson DJ; Nair P; Emmanuel B; Tran TN; Menzies-Gow A; Watt M; Kayaniyil S; Boarino S; Nuevo J
Journal
Chest, Vol. 168, No. 1, pp. 19–32
Publisher
Elsevier
Publication Date
4 2025
DOI
10.1016/j.chest.2025.04.011
ISSN
0012-3692